Close menu




November 25th, 2021 | 10:21 CET

wallstreet:online, flatexDEGIRO, Commerzbank - Here are the winners for 2022!

  • Investments
Photo credits: pixabay.com

Low interest rates and high inflation are creating strong demand for equities. Even if uncertainties about upcoming interest rate increases and the fourth Corona wave prevail, the stock market lights continue to be green. Possible price setbacks represent good entry possibilities. The following three stocks offer good opportunities.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: WALLSTREET:ONLINE INH ON | DE000A2GS609 , FLATEX AG NA O.N. | DE000FTG1111 , COMMERZBANK AG | DE000CBK1001

Table of contents:


    wallstreet:online - Undervalued

    At a price of around EUR 20, the shares of the largest independent operator of high-reach stock market portals in the German-speaking world offer an excellent entry level for investors with a medium-term horizon. In mid-June, EUR 26.60 had to be paid as part of a capital increase, bringing EUR 19.1 million gross into the Company's coffers for further expansion. In the past months, several insiders bought the shares, which is a strong sign of confidence. The analysts at GBC give the stock, which they rate as a "buy", a target price of EUR 37.70. That is an upside of over 80%!

    Where does the fantasy come from? The answer: transaction business. With the "neobroker" Smartbroker, which went to market at the end of 2019, the Berliners made a smart move. The central task now is to better integrate the Smartbroker's financial offerings into the stock market portals and thus leverage synergies and accelerate growth. Smartbroker differentiates itself to the broad field of neobrokers, which offer investors free stock trading, among other things, by providing low conditions and additionally a comprehensive product range.

    Smartbroker is currently in the process of completely revamping the trading front-end. In addition, the Smartbroker app will be launched next year. In our opinion, the associated investment costs will quickly pay for themselves. At the half-year point, the Group had more than 187,000 securities accounts, of which more than 142,000 were Smartbroker customers, with assets under management of EUR 6.8 billion. In the summer, an application was submitted to extend the existing KWG license. That means new revenue pots will soon emerge.

    For the current fiscal year, the management board forecast an increase in sales to around EUR 45 to 50 million and an increase in the operating result (EBITDA) to EUR 4 to 6 million. On December 7, the Berlin-based company will present itself at GBC's Munich investment conference "MKK". Perhaps the management will then elaborate on the growth plans for next year, which could pull the share out of its lethargy again. At around EUR 300 million, the stock is moderately valued.

    flatexDEGIRO - Management expects strong growth

    Europe's largest pan-European retail online broker most recently introduced commission-free trading from November 22, 2021. DEGIRO customers would now be able to trade over 5,000 US stocks directly on the leading US exchanges NASDAQ and NYSE across Europe without any commission. In addition, the offer applies to the French, Spanish, Portuguese and Italian markets.

    Management expects this to accelerate customer and company growth. The shares have been trading roughly in the range of EUR 18 to 20 over the last 2 months. The CEO and CFO of the companies have recently been rebuying more of their shares. According to analyst consensus, the title is currently trading at a 2022 P/E of 15. Most experts recommend "buy" with a price target of EUR 33.60 - an upside potential of over 70%.

    Commerzbank - New annual high marked briefly

    While business at wallstreet:online and flatexDEGIRO is humming, Commerzbank is making every effort to get back on the road to success. Central to this are the massive cost savings associated with the "Strategy 2024" strategy. Most recently, the MDAX-listed Group announced a significant step. Negotiations with the General Works Council to cut thousands of jobs had been successfully concluded, the Frankfurt-based Company announced most recently. "Now we can continue to drive forward the transformation swiftly and at full speed," commented Group CEO Manfred Knof.

    By year-end 2024, 10,000 of the most recent 39,500 full-time positions will be eliminated worldwide, but 2,500 posts will also be created. The bank is trying to carry out this reduction in a socially responsible manner. The branch network in Germany is to be reduced from 790 to 450 by the end of 2022. The share has reacted to the news with a new high for the year of just over EUR 7. However, the mark could only be held for a short time. Most analysts rate the Commerzbank share as a hold with a target price of around EUR 7.


    The upward trend in the stock markets continues. Investor trading activity also remains high. Thus, the shares of wallstreet:online and flatexDEGIRO should benefit. The analysts at GBC believe that wallstreet:online has an upside potential of over 80%. Commerzbank is also an exciting turnaround stock for 2022.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read